Axsome Therapeutics - Settlement in Patent Dispute With Teva Pharmaceuticals Over Antidepressant Causes the Stock to Jump!
Reading Time: 1 minute
Business drivers: The US biotech company Axsome Therapeutics (AXSM) specializes in the development of new treatments for central nervous system (CNS) disorders. With the antidepressant Auvelity (AXS-05), the company has a strong revenue-generating product that is expected to achieve sales of approximately $291.4 million in 2024. Additionally, with Sunosi (Solriamfetol), approved for the treatment of adults suffering from excessive daytime sleepiness (EDS), there is another approved product. With the FDA approval for Symbravo (AXS-07) for the acute...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
